中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

883 records (took 0.058 seconds)

    CORE AND SURFACE MODIFICATION OF MESOPOROUS SILICA NANOPARTICLES TO ACHIEVE CELL SPECIFIC TARGETING IN VIVO
    121.
    发明公开
    CORE AND SURFACE MODIFICATION OF MESOPOROUS SILICA NANOPARTICLES TO ACHIEVE CELL SPECIFIC TARGETING IN VIVO 审中-公开
    KERN- UNDOBERFLÄCHENMODIFIKATIONMESOPORÖSERSILICIUMDIOXIDNANOTEILCHENFÜRZELLSPEZIFISCHES IN VIVO-TARGETING

    公开(公告)号：EP3046547A1

    公开(公告)日：2016-07-27

    申请号：EP14846653.5

    申请日：2014-09-18

    Applicant: STC.UNM ,  SANDIA CORPORATION

    Inventor： BRINKER, Jeffrey, C. ,  TOWNSON, Jason ,  LIN, Yu-Shen ,  DURFEE, Paul, N.

    IPC: A61K9/16 ,  A61K47/34 ,  A61K47/30

    CPC classification number: A61K47/48215 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/5115 ,  A61K9/5146 ,  A61K47/02 ,  A61K47/59 ,  A61K47/60 ,  A61K47/6923 ,  A61K47/6929

    Abstract: In one aspect, the invention provides mesoporous silica nanoparticles (MSNPs), monodisperse populations of MSNPs and related protocells which exhibit single cell binding specificity to the substantial exclusion of non-targeted cells. For example, MSNPs and protocells of the invention may be used to target specific delivery of therapeutic agents to cancer cells or to specific blood vessel types (e.g. in the arterial, venous and/or capillary vessels or any combination of vessels). Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

    Abstract translation: 一方面，本发明提供介孔二氧化硅纳米颗粒（MSNP），MSNP的单分散群体和相关的原细胞，其显示出对非靶向细胞的实质排除的单细胞结合特异性。 例如，本发明的MSNP和原细胞可以用于靶向治疗剂到癌细胞或特定血管类型（例如在动脉，静脉和/或毛细血管或血管的任何组合中）的特异性递送。 还提供了相关的原细胞，药物组合物和治疗和诊断方法。

    DEVELOPMENT OF A C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS
    127.
    发明公开
    DEVELOPMENT OF A C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS 审中-公开
    C反应蛋白突变体改进治疗用途的免疫血小板减少症和狼疮性肾炎发展

    公开(公告)号：EP2303306A2

    公开(公告)日：2011-04-06

    申请号：EP09758730.7

    申请日：2009-06-02

    Applicant: STC.UNM

    Inventor： DU CLOS, Terry, W. ,  MOLD, Carolyn

    IPC: A61K38/16 ,  A61P13/12 ,  A61P19/02

    CPC classification number: A61K38/1745 ,  C07K14/4737

    Abstract: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

Patent Agency Ranking